Advertisement
Bristol Myers Squibb
Subscribe to Bristol Myers Squibb

The Lead

Photo of the Day - HIV Drug Protests in Peru

January 22, 2015 3:14 pm | by Mike Auerbach, Editor In Chief | News | Comments

In Peru, BMS' atazanavir is available as a second-line HIV drug, but its high price is out of reach of many Peruvians with HIV/AIDS.                     

Bristol-Myers Names Caforio as CEO

January 21, 2015 8:01 am | News | Comments

Bristol-Myers Squibb has named its chief operation officer, Giovanni Caforio, as its new CEO. He...

Merck Races Bristol-Myers Squibb as it Seeks New OK for Cancer Drug

January 13, 2015 8:22 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Merck is ratcheting up its race with rival Bristol-Myers Squibb Co. for leadership in one of...

Bristol-Myers' Stock Jumps on Opdivo Phase III Trial Results

January 12, 2015 8:03 am | by The Associated Press | News | Comments

Better patient survival rates prompted Bristol-Myers Squibb to bring an early end to an advanced...

View Sample

FREE Email Newsletter

Bristol-Myers Squibb and California Institute for Biomedical Research to Collaborate on New Treatment Approaches for Fibrotic Diseases

January 5, 2015 8:30 am | News | Comments

Bristol-Myers Squibb Company and the California Institute for Biomedical Research (Calibr) announced today they have entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies, and an exclusive license agreement that allows Bristol-Myers Squibb to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration.

FDA Approves BMS' Melanoma Drug

December 22, 2014 4:30 pm | News | Comments

The agency approved Opdivo for patients with hard-to-treat melanoma that cannot be removed through surgery or has spread throughout the body. The approval was based on preliminary studies showing the drug helped shrink tumors in some patients. 

GlobalData: Patent Cliff Means Pharmaceutical Companies Will Lose $65B by 2019

December 10, 2014 9:24 am | News | Comments

Pharmaceutical companies will suffer an estimated $65B drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData. The company’s report states that the drug makers hit hardest will include Otsuka, Eli Lilly, and AstraZeneca, with a significant proportion of losses coming in the Central Nervous System treatment sector.

Advertisement

FDA Blocks BMS' Hepatitis C Drug

November 26, 2014 2:11 pm | by By The Associated Press | News | Comments

U.S. regulators have declined to approve Bristol-Myers Squibb's daclatasvir as part of a combination hepatitis C treatment with another antiviral drug called asunaprevir. The company says data it submitted to the FDA to win approval of daclatasvir focused on that drug's use with asunaprevir.

BMS and Five Prime Therapeutics to Evaluate Investigational Immunotherapies Opdivo and FPA008 in Six Tumor Types

November 24, 2014 4:09 pm | News | Comments

Bristol-Myers Squibb Company and Five Prime Therapeutics have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo, Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor.

BMS to Construct a New Large-Scale Biologics Manufacturing Facility in Cruiserath, Ireland

November 17, 2014 8:31 am | News | Comments

Bristol-Myers Squibb Company has announced plans to construct a new state-of-the-art, large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland, that will produce multiple therapies for the company’s growing biologics portfolio.

Bristol-Myers Squibb to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor

November 3, 2014 7:31 pm | News | Comments

Bristol-Myers Squibb and Galecto Biotech AB have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in Phase 1 development for the treatment of idiopathic pulmonary fibrosis and other pulmonary fibrotic conditions.

Bristol-Myers Squibb Tops Wall Street Third Quarter Forecasts

October 24, 2014 8:39 am | by The Associated Press | News | Comments

Bristol-Myers Squibb reported third-quarter profit of $721 million. The New York-based company said it had profit of 43 cents per share. Earnings, adjusted for non-recurring costs, came to 45 cents per share. The results beat Wall Street expectations.

Advertisement

Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® and IMBRUVICA® in Non-Hodgkin Lymphoma

October 14, 2014 8:48 am | News | Comments

The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

Bristol-Myers Squibb Withdraws NDA for Hepatitis C Treatment

October 7, 2014 8:43 am | News | Comments

Bristol-Myers Squibb has decided that it will not pursue FDA approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1b patients in the United States and has therefore withdrawn its new drug application (NDA) for asunaprevir, an NS3/4A protease inhibitor.

Bristol-Myers Squibb and MD Anderson Cancer Center to Collaborate on Immuno-Oncology Focused Therapies for Leukemia and Hematologic Malignancies

October 6, 2014 8:10 am | News | Comments

Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo, Yervoy and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies.

Bristol-Myers Squibb to Transfer $1.4B in U.S. Pension Obligations to Prudential

October 1, 2014 8:20 am | News | Comments

Bristol-Myers Squibb Company will settle $1.4B in pension obligations through the purchase of a group annuity contract from The Prudential Insurance Company of America for approximately 8,000 U.S. retirees and their beneficiaries who started receiving their monthly retirement benefit payments on or before June 1, 2014.

Bristol-Myers Squibb to Build New Campus in Lawrenceville, NJ

September 23, 2014 12:33 pm | News | Comments

Bristol-Myers Squibb Company today announced plans to build a 650,000-square-foot office building on company-owned land at the intersection of Princeton Pike and Interstate 295 in Lawrenceville, New Jersey. Construction is expected to begin this fall and the new facility is expected to open by the end of 2016.

Advertisement

European Commission Approves Bristol-Myers Squibb’s Daklinza

August 27, 2014 8:20 am | News | Comments

Bristol-Myers Squibb Company today announced that the European Commission has approved Daklinza (daclatasvir) for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus (HCV) infection in adults.

FDA Approves Eliquis For DVT And PE

August 21, 2014 3:39 pm | by Pfizer | News | Comments

Bristol-Myers Squibb Company and Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug Application for Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. 

Bristol-Myers Squibb & Celgene Collaborate On Immunotherapy & Chemo Combination

August 20, 2014 9:59 am | by Associated Press | News | Comments

Bristol-Myers Squibb Company and Celgene Corporation announced the establishment of a clinical trial collaboration to evaluate a combination regimen of Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, OPDIVO (nivolumab), and Celgene’s chemotherapy ABRAXANE ® (paclitaxel protein-bound particles for injectable suspension), in a Phase I study.

Allied Minds and BMS Form Enterprise to Advance Discoveries of Biopharmaceutical Innovations

August 4, 2014 8:32 am | News | Comments

Allied Minds and Bristol-Myers Squibb Company today announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S.

European Commission Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism

July 29, 2014 8:38 am | News | Comments

Bristol-Myers Squibb and Pfizer announced that the European Commission has approved Eliquis for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults. The European Commission approval applies to all European Union (EU) member states as well as Iceland and Norway.

BMS Second Quarter Net Drops on Lower Drug Sales, Charges

July 24, 2014 8:15 am | News | Comments

Bristol-Myers Squibb Co.'s exit from the diabetes business, plus higher taxes and research spending, combined to slash the drugmaker's second-quarter profit by 38 percent, but the company handily beat Wall Street's muted profit expectations.

Bristol-Myers Squibb Makes Plans to Submit Biologics License Application for Opdivo®

July 10, 2014 8:12 am | News | Comments

Bristol-Myers Squibb Company today announced that, following discussions with the FDA, the company is planning a third quarter submission of a Biologics Licensing Application (BLA) for Opdivo® (nivolumab) for previously treated advanced melanoma.

Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® and Sunvepra® Dual Regimen

July 7, 2014 8:19 am | News | Comments

Bristol-Myers Squibb Company has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Daklinza® (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor ( in vitro ), and Sunvepra® (asunaprevir), a NS3/4A protease inhibitor, providing a new treatment that can lead to cure for many patients in Japan who currently have no treatment options.

BMS Issues Voluntary Nationwide Recall of COUMADIN® for Injection Due to Presence of Particulate Matter

June 30, 2014 1:40 pm | News | Comments

Bristol-Myers Squibb Company is voluntarily recalling six lots of COUMADIN® FOR INJECTION, 5 mg single-use vials in the U.S. This recall is a precautionary measure based on the company’s investigation of visible particulate matter found in a small number of COUMADIN FOR INJECTION unreleased samples.

Bristol-Myers Says Cancer Drug Met Goal in Study

June 24, 2014 7:28 pm | by The Associated Press | News | Comments

Bristol-Myers said Tuesday that its skin cancer drug nivolumab worked in a late-stage clinical trial, leading the drugmaker to end the study early. Bristol-Myers said patients treated with nivolumab lived longer than patients who received only chemotherapy.

U.S. Court of Appeals Denies Appeal in Baraclude Patent Case

June 13, 2014 7:47 am | News | Comments

Bristol-Myers Squibb Company has announced that the U.S. Court of Appeals for the Federal Circuit has denied the company’s appeal of a February 2013 ruling by the U.S. District Court for the District of Delaware that found the patent covering Baraclude (entecavir), U.S. patent 5,206,244 invalid.

Bristol-Myers Squibb and Syngene International Extend Research Collaboration

June 3, 2014 8:18 am | News | Comments

Bristol-Myers Squibb and Syngene International, India’s largest contract research organization, today announced a five-year extension of their drug discovery and development collaboration in India.         

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading